Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-07
2010-12-14
Desai, Rita J (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S317000
Reexamination Certificate
active
07851629
ABSTRACT:
The present invention relates to compounds which have therapeutic effects against disorders in the central nervous system, and in particular new 4-(ortho,meta-disubstituted phenyl)-1-alkypiperidines.wherein R1, R2, and R3 are as defined.
REFERENCES:
patent: 3326916 (1967-06-01), Creighton et al.
patent: 3539573 (1970-11-01), Hunziker et al.
patent: 4202898 (1980-05-01), Depoortere
patent: 4333942 (1982-06-01), Eistetter et al.
patent: 4415736 (1983-11-01), Ciganek et al.
patent: 4504660 (1985-03-01), Klaubert et al.
patent: 5462947 (1995-10-01), Svensson et al.
patent: 5502050 (1996-03-01), Gross
patent: 6175015 (2001-01-01), Yuan et al.
patent: 2003/0109532 (2003-06-01), Sonesson et al.
patent: 2007/0149542 (2007-06-01), Sonesson et al.
patent: 2007/0270467 (2007-11-01), Sonesson et al.
patent: 0060179 (1982-02-01), None
patent: 0369887 (1989-11-01), None
patent: 0094159 (1990-03-01), None
patent: 0533266 (1992-09-01), None
patent: 0533267 (1992-09-01), None
patent: 0533268 (1993-03-01), None
patent: 0659743 (1993-12-01), None
patent: 675118 (1995-04-01), None
patent: 1459013 (1965-05-01), None
patent: 850662 (1957-10-01), None
patent: 1560271 (1977-01-01), None
patent: 2078746 (1981-06-01), None
patent: 2083476 (1981-09-01), None
patent: 2027703 (2006-12-01), None
patent: 2000086603 (2000-03-01), None
patent: 6510107 (1966-02-01), None
patent: 8905799 (1989-06-01), None
patent: 9109594 (1991-07-01), None
patent: 9304684 (1991-12-01), None
patent: 9218475 (1992-10-01), None
patent: 9300313 (1993-01-01), None
patent: 9811068 (1998-03-01), None
patent: 0003713 (2000-01-01), None
patent: 0078728 (2000-12-01), None
patent: 0146144 (2001-06-01), None
patent: 0146145 (2001-06-01), None
patent: WO 01/46146 (2001-06-01), None
patent: WO 0146146 (2001-06-01), None
patent: 0205819 (2002-01-01), None
patent: 02059108 (2002-08-01), None
patent: 2004099150 (2004-11-01), None
patent: 2005019215 (2005-03-01), None
patent: 2005121087 (2005-12-01), None
patent: 2005121092 (2005-12-01), None
patent: 2006040156 (2006-04-01), None
patent: WO 2006/039325 (2006-04-01), None
patent: 2007042295 (2007-04-01), None
patent: 2007065655 (2007-06-01), None
Bergel et al J. Chem. Soc. 1944, 261-265.
Database Online: Chemical Abstracts Service, OH, XP002349551, Database accession No. 126:199585 compound with registry No. 187835-01-04 & Abstract WO 97/03986 A, Tanaka Hiroshi Kuroita, TA, Feb. 6, 1997.
Manoury et al., “Synthesis and Analgesic Activities of Some (4-Substituted phenyl-1-piperazinyl)alkyl 2-Aminobenzoates and 2-Aminonicotinates”; Journal of Medicinal Chemistry, 1979, vol. 22, No. 5; pp. 554-559.
Morita et al., “Practical Application of the Palladium-catalyzed Animation in Phenylpiperazine Synthesis: An Efficient Synthesis of a Metabolite of the Antipsychotic Agent Aripiprazole”; 1998 Elsevier Science Ltd., pp. 4811-4818.
Oshiro et al., “Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl) butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives”; Journal of Medicinal Chemistry, 1998 American Chemical Society; pp. 658-667.
Smaill et al., “Mono-and difunctional nitrogen mustard analogues of the DNA minor groove binder pibenzimol. Synthesis, cytotoxicity and interaction with DNA”; Anti-Cancer Drug Design (1998), vol. 13, Oxford University Press; pp. 221-242.
Beugelmans et al., “Synthese d'heterocycles a 5 et 6 chainons par une strategie combinant des reactions SNAr et SRN1”; Institut de Chimie des Substances Naturelles, 1995 vol. 132; pp. 306-313.
Egawa et al., “A New Synthesis of 7H-Pyrido[1,2,3-de][1,4]benzoxazine Derivatives Including an Antibacterial Agent, Ofloxacin”; Research Labortories, Osaka, Japan; 1986 vol. 34, pp. 4098-4102.
Takai et al., “Reaction of Spiro[4H-3,1-benzoxazine-44'-piperidin]-2(1H)-one Derivatives and Related Compounds with Phosphorus Oxychloride”; Tokyo Research Laboratory, Tokyo, Japan; pp. 1901-1906, 1986.
Zhang et al., “Acta Pharmaceutica Sinica”; 1981; vol. 16, No. 6; pp. 414-424; Shanghai Institut of Pharmaceutical Industrial Research; Shanghai.
Klaubert et al., “N-(Aminophenyl)oxamic Acids and Esters as Potent, Orally Active Antiallergy Agents”; 1989 American Chemical Society; Research Fivision, Wyeth Laboratories Incc. Radnor, Pennsylvania; Journal of Medicinal Chemistry, vol. 24; pp. 742-748.
Self et al., “cine and tele Substitutions in the Reaction of 2,3-Dinitroaniline with Secondary Amines”; J.C.S. Chem. Comm., 1980; pp. 281-282.
Elslager et al., “Folate Antagonists. 3. 2,4-Diamino-6-(heterocyclic)quinazolines, a Novel Class of Antimetabolits with Potent Antimalarial and Antibacterial Activity”; Journal of Medicinal Chemistry; 1972, vol. 15, No. 8; pp. 827-836; Department of Chemistry, Research and Development Division, Ann Arobor, Michigan.
Berberian et al., “Comparison of Schistosomicidal Activity of Xanthenones and 4-Methyl-3-chloroanilines and Their Hydroxymethyl Analogs in Swiss Mice and Syrian Hamsters Infected with Schistosoma mansoni”; Sterlin-Winthrop Research Institute, Rensselaer, New York; pp. 607-610, 1969.
David W. Henry, “A Facile Synthesis of Piperazines from Primary Amines (1)”; Department of Pharmaceutical Chemistry, Stanford Research Institute; Dec. 1966; pp. 503-511.
Bergel et al., “Synthetic Analgesics, Part 1. Synthesis of Basic Benzofuran Derivatives and Certain 4-Phenylpiperidine Compounds”; 1944; pp. 261-265.
Nacci et al., “Antiblastic substances. L11. Tylophorine analogs. 1. Synthesis and cytostotic and cytotoxic activity of 4-(3,4-dimethoxphenyl)piperidine”; Farmaco Ed. Scintifica 1972, 328, (5) pp. 399-410.
Sonesson et al., “Substituted (S)-Phenylpiperidines and Rigid Congeners as Preferential Dopamine Autoreceptor Antagonists: Synthesis and Structure-Activity Relationships”; Journal of Medicinal Chemistry, 1994 American Chemical Society; pp. 2735-2752.
Radl et al., “Synthesis of Piperidine Analogs of 1-(3-Chlorophenyl)piperazine, a Well Known Serotonin Ligand”; Research Institute for Pharmacy and Biochemistry, Prague, Czech Republic; pp. 1017-1022, 1999.
Altomare et al., “Quantitative Structure-Metabolism Relationshiop Analyses fo MAO-Mediated Toxication of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Alalogues”; Chem. Res. Toxicol, 1992, vol. 5, pp. 366-375.
Carlsson et al., Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Pakinson's disease; Department of Pharmacology, University of Goteborg, Goteborg, Sweden; 1990 Elsevier Science Publishers, vol. 13, No. 7, 1990; pp. 272-276.
Coyle et al., “Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation”; Science, vol. 219, Johns Hopkins School of Medicine, Baltimore, Maryland; pp. 1184-1190, 1983.
Grunblatt et al., “Potent neuroprotective and antioxidant activity of apomorhine in PMTP and 6-hydroxydopamine induced neurotoxicity”; Journal Neural transm. (1999) [Suppl] ; pp. 57-70.
Grunblatt et al., “Neuroprotective Strategies in Parkinson's Disease Using the Models of 6-Hydroxydopamine and MPTP”; Bruce Rappaport Family Research Institute and Department of Pharmacology, Haifa, Israel; pp. 262-273, 2000.
Philip G. Strange; “Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects”; School of Animal and Microbial Sciences, Unitversity of Reading, Whiteknights, Reading, United Kingdom, vol. 53, No. 1; pp. 119-133, 2001.
Manfred E. Wolff; “Antipsychotic Agents, 4.1 Biologic Test Methods”; Burger's Medicinal Chemistry; 4th Edition, Part III; John Wiley & Sons; 1979, pp. 872-873.
Roth et al; “Biochemical Pharmacolog of Midbrain Dopamine Neurons”; Chapter 21; Yale University of Medicine, New Haven, CT; pp. 227 and 237, 1995.
Moore et al.,
Sonesson Clas
Swanson Lars
Waters Nicholas Ross
Desai Rita J
Gauthier & Connors LLP
Mabry John
NSAB, Filial af Neurosearch Sweden AB, Sverige
LandOfFree
Disubstituted phenylpiperidines as modulators of dopamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Disubstituted phenylpiperidines as modulators of dopamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Disubstituted phenylpiperidines as modulators of dopamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172146